- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03277183
Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin
July 28, 2020 updated by: VA Office of Research and Development
Frequent, Low-Dose Erythropoietin: A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin Therapy in Patients With Chronic Kidney Disease
Although several large well designed clinical trials have shown that erythropoietin which is commonly used to treat anemia associated with kidney disease, increases the risk of stroke and heart disease, the mechanism for this increased risk is unknown.
The investigators' preliminary studies show that the adverse effects of erythropoietin are from activation of the heterodimeric erythropoietin/ beta common receptor which only occurs with high doses of erythropoietin.
The investigators propose a clinical trial of 120 patients assigned to low doses of erythropoietin given more frequently or the same cumulative dose of erythropoietin administered as a high dose once every two weeks and assess effects on the beta common receptor activation, inflammation and vascular disease as evidence by MRI of the carotid arteries.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Erythropoietin (EPO) is the most widely prescribed cytokine, yet the benefits and potential side effects of different dosing regimens are poorly understood.
It is now recognized that erythropoietin administered at high doses to patients with chronic kidney disease, results in an increased risk of morbidity and mortality from heart disease and stroke.
However, the mechanisms that mediate this increased risk of cardiovascular disease is not known.
There are two receptors for erythropoietin the homodimeric EPO receptor (EPOR) and the heterodimeric beta common receptor ( CR)/EPOR.
The investigators have demonstrated that activation of the heterodimeric CR/EPOR only occurs with high doses of EPO.
Our exciting, published, preliminary data also demonstrates that the CR is in a complex with vascular endothelial growth factor receptor-2 (VEGFR-2) and that high doses of EPO activate VEGFR-2 through the CR, resulting in the deleterious effects of VEGFR-2 activation on the cardiovascular system.
This is particularly important in patients with kidney disease since they are already at a high risk of cardiovascular disease.
Moreover in advanced kidney disease cyanate derived from the high urea levels can non-enzymatically form an amide bond with EPO.
This carbamylated EPO (cEPO) has no effect on hemoglobin, but still activates the heterodimeric CR/EPOR.
To date there have been no studies that have directly measured levels of cEPO or activation of the CR/EPOR in patients with kidney disease.
Our hypothesis is that the administration of low-doses of EPO more frequently will result in lower levels of total and carbamylated erythropoietin decreased activation of VEGFR-2 via the heterodimeric CR/EPOR and consequently decreased inflammation and atherosclerosis.
The investigators will directly test this hypothesis by randomly allocating 120 patients with chronic kidney disease to either low- dose EPO given thrice weekly or the same cumulative dose, a high-dose, administered once every 2 weeks.
Our hypothesis predicts that low-dose EPO will be as effective at correcting anemia, but will demonstrate less progression of carotid artery plaque, as assessed by non-contrast magnetic resonance imaging, as compared to the high-dose, EPO given every 2 weeks.
To delineate how EPO affects blood vessels, the investigators will isolate endothelial cells from blood vessels in 20 patients who are assigned to low-dose EPO and 20 allocated to high-dose EPO.
Within these cells the investigators will investigate the signaling pathways that are triggered by activation of CR/EPOR.
In a substudy of 20 subjects with kidney disease randomized to low-dose EPO or to high-dose EPO, as well as 20 healthy controls receiving a single dose of high- or low-dose EPO, the investigators will determine how kidney function and dosing affects levels of total and carbamylated erythropoietin.
The investigators' study will not only provide us with a thorough understanding of the mechanism by which EPO mediates the increased risk of atherosclerosis, but a clinical strategy to avoid the side effects of EPO therapy and a tool to quantify the cardiovascular risk of EPO and newer erythropoiesis stimulating agents by assessing activation of the heterodimeric CR/EPOR.
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32608
- North Florida/South Georgia Veterans Health System, Gainesville, FL
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
The investigators will enroll Veterans who fulfill the following criteria:
- stage 3, 4, or 5 CKD (estimated glomerular filtration rate of less than 60 ml/min/1.73 m2) on at least two separate occasions greater than 3 months apart; and
- candidates for EPO therapy as per the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative guidelines (hemoglobin < 10 gm/dL and anemia of CKD).
Exclusion Criteria:
The investigators will exclude any Veteran who meets any of the following criteria:
- pregnant, planning to become pregnant in the next year, or breast feeding;
- uncontrolled hypertension (blood pressure > 180/100 mm Hg despite optimal antihypertensive medications);
- active gastrointestinal bleeding (visible blood or positive tests for stool occult blood accompanied by a decrease in hemoglobin);
- likely to have EPO resistance;
- an adverse cardiovascular event in the prior three months;
- active or recent (within the last 3 months) severe, systemic infection;
- active inflammatory disease such as lupus, rheumatoid arthritis, or vasculitis requiring immunosuppressive or immunomodulatory medications;
- history of solid organ transplantation;
- expected off-dialysis survival of less than one year (as determined by the estimated glomerular filtration slope and the treating physician;
- active cancer (undergoing chemotherapy or radiation within the last 3 months) or primary bone marrow disease such as myelofibrosis; or
- a contraindication for an MRI or individuals who cannot comply with the study protocol. The investigators will exclude healthy subjects that meet a, b, f, g, h, or j.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Low dose erythropoietin
Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly
|
Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly
Other Names:
|
EXPERIMENTAL: High dose erythropoietin
Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks
|
Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Carotid Total Plaque Volume From Baseline to Approximately 1 Year, as Assessed by Non-contrast MRI
Time Frame: 1 year
|
The plaque characteristics will be analyzed by MRI-PlaqueViewTM (VP diagnostics Inc., WA).
Planimetry will be performed on the image data sets, using histogram equalization to improve edge detection for plaque, arterial wall and lumen.
Differences in image contrast between T1-weighted, T2-weighted, Time of Flight, and proton density will be used to characterize the plaque as fibrous, stable, or unstable.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Severity of Maximal Stenosis at Baseline and Upon Follow-up.
Time Frame: 1 year
|
The plaque characteristics will be analyzed by MRI-PlaqueViewTM (VP diagnostics Inc., WA).
Planimetry will be performed on the image data sets, using histogram equalization to improve edge detection for plaque, arterial wall and lumen.
Differences in image contrast between T1-weighted, T2-weighted, Time of Flight, and proton density will be used to characterize the plaque as fibrous, stable, or unstable.
|
1 year
|
Percentage of Total Plaque Area at Baseline and Upon Follow-up.
Time Frame: 1 year
|
The plaque characteristics will be analyzed by MRI-PlaqueViewTM (VP diagnostics Inc., WA).
Planimetry will be performed on the image data sets, using histogram equalization to improve edge detection for plaque, arterial wall and lumen.
Differences in image contrast between T1-weighted, T2-weighted, Time of Flight, and proton density will be used to characterize the plaque as fibrous, stable, or unstable.
|
1 year
|
Characteristics of Plaques (Soft or Fibrous and Stable or Unstable) at Baseline and Upon Follow-up.
Time Frame: 1 year
|
The plaque characteristics will be analyzed by MRI-PlaqueViewTM (VP diagnostics Inc., WA).
Planimetry will be performed on the image data sets, using histogram equalization to improve edge detection for plaque, arterial wall and lumen.
Differences in image contrast between T1-weighted, T2-weighted, Time of Flight, and proton density will be used to characterize the plaque as fibrous, stable, or unstable.
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Mark S. Segal, MD PhD, North Florida/South Georgia Veterans Health System, Gainesville, FL
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 2, 2017
Primary Completion (ACTUAL)
June 3, 2019
Study Completion (ACTUAL)
June 3, 2019
Study Registration Dates
First Submitted
September 6, 2017
First Submitted That Met QC Criteria
September 6, 2017
First Posted (ACTUAL)
September 8, 2017
Study Record Updates
Last Update Posted (ACTUAL)
August 13, 2020
Last Update Submitted That Met QC Criteria
July 28, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CARA-019-16F
- I01CX001449 (NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atherosclerosis
-
University Hospital, CaenUnknownPeripheral Arterial Disease | Atherosclerosis Obliterans | Atherosclerosis Right Leg | Atherosclerosis Left LegFrance
-
Nantes University HospitalAbbottCompletedAtherosclerosis ObliteransFrance
-
Central Hospital, Nancy, FranceSuspended
-
Federal University of São PauloCompletedAtherosclerosis of ArteryBrazil
-
MedtronicActive, not recruitingAtherosclerosis of Femoral Artery | Obstructive Disease | Atherosclerosis of Popliteal ArteryFrance
-
Cabinet de Medecine Interne Générale Demetrio PitarchCompletedAtherosclerosis of Artery
-
Emory UniversityThe Robert W. Woodruff FoundationCompleted
-
Korea UniversityMinistry of Health & Welfare, KoreaCompletedAtherosclerosis | Noninvasive Imaging of AtherosclerosisKorea, Republic of
-
Zhejiang Zylox Medical Device Co., Ltd.RecruitingAtherosclerosis of Femoral ArteryGermany
-
VA Office of Research and DevelopmentCompletedSaphenous Vein Graft AtherosclerosisUnited States
Clinical Trials on Low dose erythropoietin
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedPneumonia | Coronavirus Infection in 2019 (COVID-19) | Severe Acute Respiratory Syndrome (SARS) PneumoniaUnited States
-
MedImmune LLCCompletedNon-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)United States, Puerto Rico
-
Beijing Northland Biotech. Co., Ltd.CompletedSafety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.InfarctionAcute Myocardial InfarctionChina
-
MegalabsNot yet recruiting
-
Lucozade Ribena SuntoryKing's College LondonCompletedPostprandial PeriodUnited Kingdom
-
Indonesia UniversityMedika Natura Sdn BhdCompleted
-
Postgraduate Institute of Medical Education and...Completed
-
Yiling Pharmaceutical Inc.CompletedPharmacokinetics | Healthy Adult Subjects | Safety and TolerabilityUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingLung CarcinomaUnited States